In March 2021, Delnevo was appointed to serve as a member of the Tobacco Products Scientific Advisory Committee (TPSAC) until January 2025. TPSAC is responsible for reviewing and evaluating the safety and health risks associated with tobacco products and providing relevant information and recommendations to the FDA Commissioner. Committee members are selected from individuals with expertise in medical, scientific, or technical fields related to the manufacture and use of tobacco products.
Delnevo stated, "Since the signing of the Family Smoking Prevention and Tobacco Control Act in 2009, I have placed great importance on the FDA Advisory Committee. This committee plays an important role in various aspects, perhaps most notably in reviewing modified risk tobacco product applications as required by the Tobacco Control Act. I value the service of Dr. Jonathan Samet and Dr. Robin Mermelstein who will serve as chair in front of me. I look forward to working with a group of respected colleagues to help the FDA make regulatory decisions that protect public health and reduce tobacco-related morbidity and mortality.
Recent Suspicious FDA Resignations
In other FDA-related news, it was recently announced that Matthew Holman, who became the director of the CTP just last month, has stated that he will be "immediately effective" in his role. Holman, who previously worked as an operating systems manager, revealed that he had been on leave "prior to my appointment at the center" and indicated that "in accordance with agency ethics policy, he would recuse himself from all CTP/FDA work while exploring job opportunities outside of government.
Amanda Wheeler, the president of a US vape manufacturer and a vape shop owner in Arizona, believes that there is more to the story regarding the recent resignation of FDA Commissioner Scott Gottlieb. In an interview with Filter, Wheeler stated, "Holman isn't leaving the FDA, he's running away. It's hard to avoid the feeling that the most serious and important work of reducing tobacco harm is being done outside of an institution that seems irreparable.
Just a few days ago, Robert Califf, head of the FDA, announced that he will commission an "extensive evaluation" of CTP by external experts. It is well-known that the FDA has faced criticism for approving safer nicotine replacement products due to various reasons. Similarly, the agency was strongly criticized last month by Senator Dick Durbin (D-Illinois) and Susan Collins (R-Maine). In a letter, the senators cited a STAT report that criticized the agency for not taking action on the synthetic nicotine ban announced earlier this year, stating that the FDA "seems to once again fail to protect our nation's children.
Statement:
This article has been compiled from third-party information and is only intended for industry professionals to enhance their knowledge and exchange ideas.
This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is solely for the purpose of industry exchange and research.
Due to limitations in our translation abilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
